Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Tanya Skamene, MD, Wenyu Jiang, PhD, Ralph M. Meyer, MD, Michael Crump, MD, John Kuruvilla, MD, C. Tom Kouroukis, MD MSc, FRCPC, Stefano Luminari, Stephen Couban, MD, Matthew C. Cheung, MD SM, FRCPC, David A Rizzieri, MD, Peter G Bardy, MBBS, FRACP, FRCPA, Joseph Pater, MD MSc, Marina S. Djurfeldt, MSc, Lois E. Shepherd, MD, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 690.

https://doi.org/10.1182/blood.V128.22.690.690

Published: 2016

Journal Articles

Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium

Suzanne Trudel, MD, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Annette E Hay, MB ChB, Olena Kis, PhD, Signy Chow, MD FRCPC, Zhi Hua Li, MD, Ellen Nong Wei, MSc, Lisa Wang, PhD, Christine Tran, Smitha Udagani, Chantale Blattler, Trevor J. Pugh, PhD, Helen X Chen, MD, Amit Oza, MD

Blood (2016) 128 (22): 4526.

https://doi.org/10.1182/blood.V128.22.4526.4526

Published: 2016

Journal Articles

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Tony Reiman, MD, Kerry J. Savage, MD MSc, Michael Crump, MD, Matthew Cheung, MD, David A. MacDonald, MD, Rena Buckstein, MD, Stephen Couban, MD, Eugenia Piliotis, MD, Kevin R Imrie, MD, David Spaner, MD PhD, Sudeep Shivakumar, MD, John Kuruvilla, MD, Diego Villa, Lois E. Shepherd, MD, Tanya Skamene, MD, Chad Winch, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 4162.

https://doi.org/10.1182/blood.V128.22.4162.4162

Published: 2016

Journal Articles

Testing for Heparin Induced Thrombocytopenia: Comparison of Practice at an Academic Center with Choosing Wisely Guidelines

DiMaria C Erica, MD, Alex Trussler, MD, Dyba Janique, MD, David Lee, MD FRCPC, Michael J. Rauh, MD PhD, Paula D. James, MD FRCPC, Wilma Hopman, MA, Annette E Hay, MB ChB

Blood (2015) 126 (23): 3469.

https://doi.org/10.1182/blood.V126.23.3469.3469

Published: 2015

Journal Articles

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Ming Han, BSc., Alli Murugesan, MSc, PhD, Nizar J Bahlis, MD, Kevin Song, Darrell White, MD MSc, FRCPC, FACP, Christine Chen, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kang Howsen-Jan, MD, Donna Reece, Keith Stewart, MD, Yagang Xie, MD PhD FCCMG, Annette E Hay, MB ChB, Lois Shepherd, MD, Bingshu E Chen, PhD, Marina Djurfeldt, MSc., Tony Reiman, MD

Blood (2015) 126 (23): 2960.

https://doi.org/10.1182/blood.V126.23.2960.2960

Published: 2015

Journal Articles

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

Annette E Hay, MB ChB, Alli Murugesan, PhD, Ashley M. DiPasquale, BSc, Tom Kouroukis, MD MSc, FRCPC, Irwindeep Sandhu, MD FRCPC, Vishal Kukreti, MD, Nizar J Bahlis, MD, Johan Lategan, MD, Donna E. Reece, MD, John F. Lyons, PhD, Joana Sederias, MSc, Jean Powers, MSc, Hao Xu, MSc, Lesley K. Seymour, MD PhD FRCP (C), Anthony Reiman, MD

Blood (2014) 124 (21): 5734.

https://doi.org/10.1182/blood.V124.21.5734.5734

Published: 2014

Journal Articles

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Tara Baetz, MD, Bingshu E Chen, PhD, Stephen Couban, MD, C. Tom Kouroukis, MD MSc, FRCPC, Rena Buckstein, MD, John Kuruvilla, MD, Kang Howson-Jan, David Szwajcer, MD FRCPC, Massimo Federico, MD, Ralph M. Meyer, Robert Turner, MD, Marina S Djurfeldt, MSc, Annette E Hay, MB ChB, Lois Shepherd, MD, Michael Crump, MD

Blood (2014) 124 (21): 1712.

https://doi.org/10.1182/blood.V124.21.1712.1712

Published: 2014

Journal Articles

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193

Matthew D. Seftel, MDMPH FRCPC, John Kuruvilla, MD, Versha Banerji, MD, Graeme Fraser, MDFRCPC, Hao Xu, MSc, Jean Powers, MSc, Susan Crocker, PhD, Marcia Toguchi, PhD, John F Lyons, PhD, Lesley Seymour, MDPhD, Annette E Hay, MB ChB

Blood (2014) 124 (21): 5670.

https://doi.org/10.1182/blood.V124.21.5670.5670

Published: 2014

NARROW

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Testing for Heparin Induced Thrombocytopenia: Comparison of Practice at an Academic Center with Choosing Wisely Guidelines

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only